AbbVie
ABBV
2,982 hedge funds and large institutions have $161B invested in AbbVie in 2021 Q4 according to their latest regulatory filings, with 456 funds opening new positions, 1,280 increasing their positions, 920 reducing their positions, and 87 closing their positions.
424% more first-time investments, than exits
New positions opened: 456 | Existing positions closed: 87
60% more funds holding in top 10
Funds holding in top 10: 134 → 214 (+80)
39% more repeat investments, than reductions
Existing positions increased: 1,280 | Existing positions reduced: 920
32% more call options, than puts
Call options by funds: $4.17B | Put options by funds: $3.15B
27% more capital invested
Capital invested by funds: $127B → $161B (+$33.8B)
12% more funds holding
Funds holding: 2,655 → 2,982 (+327)
0.73% more ownership
Funds ownership: 66.69% → 67.42% (+0.73%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
T. Rowe Price Associates
Baltimore,
Maryland
|
+$753M |
| 2 |
Franklin Resources
San Mateo,
California
|
+$384M |
| 3 |
Ameriprise
Minneapolis,
Minnesota
|
+$315M |
| 4 |
State Street
Boston,
Massachusetts
|
+$307M |
| 5 |
Capital International Investors
Los Angeles,
California
|
+$226M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Berkshire Hathaway
Omaha,
Nebraska
|
-$1.34B |
| 2 |
Fidelity Investments
Boston,
Massachusetts
|
-$538M |
| 3 |
Assenagon Asset Management
Senningerberg,
Luxembourg
|
-$311M |
| 4 |
OAG
Orbis Allan Gray
Hamilton,
Bermuda
|
-$298M |
| 5 |
Wells Fargo
San Francisco,
California
|
-$212M |
ABBV Hedge Fund Activity: Q4 2021 in Review
2,982 of the 6,499 institutional investors tracked by Wall St. Rank reported a position in AbbVie (ABBV) for Q4 2021, worth a combined $161B — up 27% from $127B a quarter earlier.
Buyers outnumbered sellers: 456 funds opened new ABBV positions and 87 closed out — a net gain of 369 holders — while 1,280 added to existing stakes and 920 trimmed.
The largest buyer was T. Rowe Price Associates, adding an estimated $753M. The largest seller was Berkshire Hathaway, cutting an estimated $1.34B.
- 2,982 institutional investors held AbbVie (ABBV) as of Q4 2021, up from 2,655 in Q3 2021.
- Funds reported $161B of AbbVie stock for Q4 2021, up 27% quarter-over-quarter.
- 456 funds opened new AbbVie positions in Q4 2021 and 87 closed out, a net change of +369 holders.
- The largest AbbVie buyer in Q4 2021 was T. Rowe Price Associates, an estimated $753M added.
- The largest AbbVie seller in Q4 2021 was Berkshire Hathaway, an estimated $1.34B sold.
Based on aggregated 13F filings for Q4 2021.